Catalent Supplies ODTs to Otsuka, Makes Extensive Investments in UK
Catalent recently announced it has commenced supply to Otsuka Pharmaceutical Co., Ltd. of Abilify OD Tablets (orally disintegrating tablets, ODTs), which utilize Catalent’s Zydis fast-dissolve drug delivery technology.
Otsuka is one of the leading innovative pharmaceutical companies in
Additionally, to support the increasing demand for Zydis ODT formulations from the Japanese market, Catalent intends to make multi-million dollar investments to its Zydis ODT operations in
“We are delighted to partner with Otsuka on the launch of this important new formulation of Abilify OD,” said Dr. Ian Muir, President of Catalent’s Modified Release Technology business. “Catalent’s Zydis fast-dissolve technology has provided a tablet that is very palatable, and disintegrates within seconds in the mouth, making it very easy to take. As patient medication compliance is critical for those requiring antipsychotic therapies, Otsuka believes this new formulation will be of great assistance to patients in
“We are very excited with the growing demand for Catalent’s Zydis ODT in Japan, where many products could benefit from this type of ODT formulation,” added Mr. Hans-Joachim Rohe, President of Catalent Japan. “We have seen an increasing number of customers specifically seeking truly rapid disintegration and superior palatability in order to differentiate their products in
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings, and the most unique technologies in the industry. For more information, visit www.catalent.com.
Total Page Views: 893
